Somatic alterations in cellular DNA underlie almost all human cancers 1 . The prospect of targeted therapies 2 and the development of high-resolution, genome-wide approaches [3] [4] [5] [6] [7] [8] are now spurring systematic efforts to characterize cancer genomes. Here we report a large-scale project to characterize copy-number alterations in primary lung adenocarcinomas. By analysis of a large collection of tumours (n 5 371) using dense single nucleotide polymorphism arrays, we identify a total of 57 significantly recurrent events. We find that 26 of 39 autosomal chromosome arms show consistent large-scale copy-number gain or loss, of which only a handful have been linked to a specific gene. We also identify 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions. Only six of these focal events are currently associated with known mutations in lung carcinomas. The most common event, amplification of chromosome 14q13.3, is found in 12% of samples. On the basis of genomic and functional analyses, we identify NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineagespecific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung adenocarcinomas. More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered.
A collection of 528 snap-frozen lung adenocarcinoma resection specimens, with at least 70% estimated tumour content, was selected by a panel of thoracic pathologists (Supplementary Table 1) ; samples were anonymized to protect patient privacy. Tumour and normal DNAs were hybridized to Affymetrix 250K Sty single nucleotide polymorphism (SNP) arrays. Genomic copy number for each of over 238,000 probe sets was determined by calculating the intensity ratio between the tumour DNA and the average of a set of normal DNAs 9, 10 . Segmented copy numbers for each tumour were inferred with the GLAD (gain and loss analysis of DNA) algorithm 11 and normalized to a median of two copies. Each copy number profile was then subjected to quality control, resulting in 371 high-quality samples used for further analysis, of which 242 had matched normal samples (Methods).
To identify regions of copy-number alteration, we applied GISTIC (genomic identification of significant targets in cancer) 12 , a statistical method that calculates a score that is based on both the amplitude and frequency of copy-number changes at each position in the genome, using permutation testing to determine significance (Methods).
GISTIC identified 26 large-scale events and 31 focal events, reported below. Although the overall pattern is broadly consistent with the literature on lung cancer 8, [13] [14] [15] , our sample size and resolution provide more power to accurately identify and localize both large-scale and focal chromosomal alterations. With respect to large-scale events, no single previous study has identified more than 5 of the gains or 11 of the losses 13, 14 (Supplementary Table 2 ). With respect to focal events, three recent studies 8, 14, 15 report a total of ,200 events, including 23 of the 31 recurrent focal events observed in our study. The overlap among these three studies is limited to only four events (amplification of EGFR, CCNE1, MDM2 and 8p11, all seen here; Supplementary Table 3 and Supplementary Results). A genome-wide view of segmented copy number reveals that most chromosomal arms undergo either amplification or deletion across a large proportion of the samples (Fig. 1a) . The distinctive pattern of amplification and loss is also apparent when the median copy number for each chromosome arm is plotted ( Supplementary Fig. 1 and Supplementary Table 4 ). In total, GISTIC identifies 26 large segments (at least half of a chromosome arm), 10 with significant gains and 16 with significant losses (Fig. 1b and Supplementary Table 5 ).
Visual inspection reveals that similar chromosomal patterns of copy number loss and gain across the genome are found in almost all samples, but that the samples show substantial differences in the amplitude of copy-number variation (Fig. 1a) . When the samples are partitioned into tertiles on the basis of overall variation in copynumber amplitude, each shows similar regions of amplification and loss across the genome. The attenuation seen in many samples is consistent with admixture with euploid non-tumour DNA, which we estimate at 50%, 65% and 78% respectively in the three tertiles (Supplementary Results and Supplementary Fig. 2 ). The significant non-tumour admixture in these tumour samples also makes it difficult to assess genome-wide loss of heterozygosity (LOH). Because normal DNA admixture limits sensitivity, we report LOH only in the top tertile; we see both LOH associated with copy-number loss and copy-neutral LOH (chromosomes 17p and 19p) (Supplementary Results, Supplementary Figs 3 a, Smoothed copy number data for 371 lung adenocarcinoma samples (columns; ordered by degree of interchromosomal variation and divided into top, middle and bottom tertiles) is shown by genomic location (rows). The colour scale ranges from blue (deletion) through white (neutral; two copies in diploid specimens) to red (amplification). b, c, False-discovery rates (q values; green line is 0.25 cut-off for significance) and scores for each alteration (x axis) are plotted at each genome position (y axis); dotted lines indicate the centromeres. Amplifications (red lines) and deletions (blue lines) are shown for large-scale events (b; $50% of a chromosome arm; copy number threshold 5 2.14 and 1.87) and focal events (c; copy number threshold 5 3.6 and 1.2). Open circles label known or presumed germline copy-number polymorphisms.
The most common genomic alteration in lung adenocarcinoma is copy-number gain of chromosome 5p, which is found in 60% of total samples and over 80% of the top tertile (Supplementary Table 5 ). Another 15 large-scale events are seen in at least 33% of all samples and over 40% of the top tertile. Together, the regions of common copy-number gain (,650 megabases (Mb)) and copy-number loss (,1,010 Mb) comprise more than half of the human genome (Supplementary Results and Supplementary Table 5 ). Despite their high frequency, few of these large-scale events have been clearly related to functional effects on specific genes. Loss of a chromosome arm is likely to act by uncovering an inactivated tumour suppressor gene, yet such mutations have been well-established in lung adenocarcinoma in only three of the sixteen deleted chromosome arms (CDKN2A on 9p, TP53 on 17p and STK11 on 19p) [16] [17] [18] . We tested for correlations between the large-scale lesions and clinical parameters, but none was significant after correction for multiple hypothesis testing (Supplementary Results and Supplementary Table 7) .
Focal deletions may help pinpoint tumour suppressor genes, particularly on chromosome arms that show frequent copy-number loss. At a threshold set to detect homozygous deletions in the presence of stromal contamination, GISTIC analysis identified seven focal candidate regions ( Fig. 1c and Supplementary Table 8 ). The most significant focal deletions, detected in 3% of all samples and 6.5% of the top tertile, encompass CDKN2A/CDKN2B, two well-documented tumour suppressor genes on chromosome 9p21 (Fig. 1c , Table 1 and Supplementary Table 8 ). The protein products of CDKN2A and CDKN2B inhibit two cyclin-dependent kinases, Cdk4 and Cdk6, the genes of which both reside in frequently amplified regions (see below). Two other deleted regions also encompass known tumour suppressor genes, PTEN and RB1 (Supplementary Table 8 ).
Three additional deletion regions each localize to a single gene. Deletions of the 59 untranslated region of PTPRD, encoding a tyrosine phosphatase, occur in 4% of the top tertile. Although PTPRD deletions have been reported in lung adenocarcinoma cell lines 8, 19, 20 , this is the first observation in primary human lung adenocarcinomas. Homozygous deletions of PDE4D occur in 1.6% of the top tertile and typically remove several hundred kilobases and affect multiple exons ( Supplementary Fig. 5 ). These deletions may be significant for lung biology because PDE4D encodes the major phosphodiesterase responsible for degrading cyclic AMP in airway epithelial cells 21 . Another single-gene deletion occurs within AUTS2, a gene of unknown function in chromosome 7q11.22 (Table 1 and Supplementary Table 8 ). We cannot exclude the possibility that some recurrent copy-number losses are due to genomic fragility unrelated to carcinogenesis; the presence of point mutations would provide additional support for a role in cancer.
We therefore sequenced all exons of AUTS2, PDE4D and PTPRD, as each of these genes showed single-gene deletions but no mutations have been reported in primary tumours. Although we did not detect somatic mutations in AUTS2 or PDE4D, we identified validated somatic PTPRD mutations in 11 of 188 samples sequenced. Notably, three of the mutations encode predicted inactivating changes in the tyrosine phosphatase domain (Supplementary Table  9 and Supplementary Fig. 6 ). These results implicate PTPRD as a probable cancer-associated gene, although further studies are needed to establish a causative role in cancer via gain or loss of function.
We focused above on homozygous deletions, but note that this approach will miss important genes. Notably, the TP53 locus is known to be mutated in ,50% of lung adenocarcinomas but shows no homozygous deletions in our data.
We next focused on focal amplification events, for which it may be easier to pinpoint target genes. At a threshold designed to identify high-copy amplification, the GISTIC analysis identified 24 recurrent genomic segments with maximum copy number ranging from about 4-to 16-fold (Fig. 1c , Table 1 and Supplementary Table 10 ). The amplification events are seen in 1-7% of all samples (1-12% in the top tertile). Each of these events is seen in at least two samples and all but eight are seen in at least five samples. In the 13 most significant amplifications (q , 0.01), the regions can be localized to relatively small genomic segments containing 15 or fewer genes. Although 14 of the 24 regions of recurrent amplification contain a known protooncogene (Supplementary Table 10 ), only three of these genes (EGFR, KRAS and ERBB2) have been previously reported to be mutated in lung adenocarcinoma (Supplementary Results). The remaining 11 genes are clear targets for re-sequencing in lung tumours. 
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Our data localize the amplification peak on chromosome 5p to the telomerase catalytic subunit gene, TERT. Although broad amplification of chromosome 5p has been described in non-small-cell lung cancer (NSCLC) 13, 22, 23 , the target of 5p amplification has not been determined. In our data set, eight tumours with amplicons in chromosome 5p15 delineate a region containing ten genes, including TERT (Table 1 and Supplementary Table 10 ), suggesting that TERT may be the target of the amplification and thereby contributes to cellular immortalization.
Chromosome 6p21.1 shows focal amplification in four samples in a region containing two genes, one of which (VEGFA) encodes vascular endothelial growth factor (Table 1 and Supplementary Table  10 ). This amplification suggests a possible mechanism for increased angiogenesis and for the reported response to angiogenic inhibitors such as the anti-VEGF antibody bevacizumab in lung adenocarcinoma 24, 25 . Similarly, amplification of regions including several cell cycle genes such as CDK4, CDK6 and CCND1 suggests an important role for these genes (Table 1 and Supplementary Table 10) .
Notably, the most common focal amplification does not include any known proto-oncogenes: chromosome 14q13.3 is amplified in 6% of the samples overall and 12% of the samples in the top tertile (Fig. 1c , Table 1 and Supplementary Table 10 ; q , 10 228 ). Although previous studies have reported amplification of 14q13 in lung cancer cell lines 14 and the region is mentioned in studies of primary lung tumours 8, 15 , the target gene in this region had not been identified. With our large sample size, we are able to narrow the critical region to a 480-kilobase interval containing only two known genes, MBIP and NKX2-1 (Fig. 2a, b , Table 1 and Supplementary Table 10 ). Data for a single tumour with a small region of high-level amplification, comprising MBIP and NKX2-1, exclude the neighbouring gene, NKX2-8 (Fig. 2c) .
We confirmed the amplification of the region by fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (qPCR; data not shown). FISH analysis was performed with a bacterial artificial chromosome (BAC) probe containing NKX2-1 and NKX2-8 (Fig. 2c) on an independent set of 330 lung adenocarcinoma samples from tissue microarrays. High-level amplification of the chromosome 14q13.3 region was seen in 12% (40 out of 330) of these lung tumours. The FISH studies revealed amplification up to an estimated 100-fold ( Fig. 2d and Supplementary Fig. 7) ; the lower amplification estimated on the SNP arrays (up to 14-fold) probably reflects signal saturation, stromal admixture and tumour heterogeneity. No significant difference in patient survival after surgical resection and long-term follow-up was observed between tumours with amplified or non-amplified NKX2-1 ( Supplementary Fig. 8 and Supplementary Table 11) . Exon-based sequencing in 384 lung adenocarcinoma DNA samples showed no somatic mutations in either NKX2-1 or MBIP (Supplementary Results), indicating that any oncogenic function might be exerted by the wild-type gene.
We used RNA interference (RNAi) to test the roles of both MBIP and NKX2-1 with respect to cell survival and oncogenic properties. Expression of two different short hairpin RNAs (shRNAs) targeting NKX2-1 significantly reduced the levels of NKX2-1 protein in NCI-H2009 cells (Fig. 3a) and NCI-H661 cells (data not shown)-NSCLC lines that carry 14q amplifications 14 . No NKX2-1 protein was detected in A549 cells that lack 14q amplification (Fig. 3a) .
RNAi-mediated inhibition of NKX2-1 expression substantially decreased the ability of NCI-H2009 cells to grow in an anchorageindependent manner as measured by colony formation in soft agar (Fig. 3b) , which may be due, in part, to a loss of cell viability. NCI-H661 cell viability was also impaired by NKX2-1 RNAi (Supplementary Fig. 9 ). NKX2-1 knockdown leads to a decrease in colony formation in lung adenocarcinoma lines (NCI-H1975 and HCC1171) that lack chromosome 14q13 amplification but express NKX2-1 ( Supplementary Fig. 10 ), but has no effect on either soft agar colony formation or cell viability in A549 cells, which express little or no NKX2-1 protein (Fig. 3a, c) . In contrast to the results for NKX2-1, RNAi-based MBIP knockdown neither decreased colony formation in NCI-H2009 cells (Fig. 3d, e) or in NCI-H661 cells ( Supplementary  Fig. 11a, b) , nor reduced cell viability ( Supplementary Fig. 11c, d ). It thus seems that NKX2-1, but not MBIP, is essential for the survival and tumorigenic properties of lung adenocarcinoma cell lines that express NKX2-1.
Systematic understanding of the molecular basis of a particular type of cancer will require at least three steps: comprehensive characterization of recurrent genomic aberrations (including copynumber changes, nucleotide sequence changes, chromosomal rearrangements and epigenetic alterations); elucidation of their biological role in cancer pathogenesis; and evaluation of their utility for diagnostics, prognostics and therapeutics. This study represents a step towards comprehensive genomic characterization of one of the most common cancers, lung adenocarcinoma. We define two main types of recurrent events in this disease: frequent, large-scale events and rare, focal events. Further efforts to identify the target genes of the frequent, large-scale events will probably involve systematic screens to produce orthogonal data sets (mutational, epigenetic, expression and loss-of-function phenotypes).
Strikingly, the single most common focal event in lung adenocarcinoma (amplification of 14q13.3) was not previously associated with a specific gene. We show here that the target gene is NKX2-1, a transcription factor that has an essential role in the formation of type II pneumocytes, the cell type that lines the alveoli of the lung 26, 27 . Nkx2-1 knockout mice fail to develop normal type II pneumocytes or alveoli and die of respiratory insufficiency at birth 28 , which highlights the importance of NKX2-1 in lung development. NKX2-1 shows hallmarks of a novel lineage-survival oncogene, similar to the MITF gene in melanoma 7 . The lineage-restricted amplification of such genes contrasts with the more ubiquitous amplifications seen for genes in cell cycle (for example, CDK4, CDK6, CCND1, CCNE1) and signal transduction (for example, EGFR, ERBB2, KRAS) pathways.
More generally, our results, together with other recent studies 29 , illustrate the power of systematic copy-number analysis with SNP arrays. They make clear that many important cancer-related genes remain to be discovered and can be revealed by systematic genomic study.
METHODS SUMMARY
DNA specimens were labelled and hybridized to the Affymetrix 250K Sty I array to obtain signal intensities and genotype calls. Loci identified by GISTIC analysis were further characterized by sequencing, genotype validation, tissue microarray FISH and functional studies. RNAi was performed by stable expression of shRNA lentiviral vectors targeting NKX2-1, MBIP or GFP in lung cancer cell lines, which were then used in soft agar and cell proliferation assays. Raw data and related files are available at http://www.broad.mit.edu/tsp.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
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, the number of times the smoothed copy number crossed 60.1 on the log scale in the genome of tumour samples was , 100 (removing 73 tumours). The same test was used to exclude normal samples, with the number of times the smoothed copy number crossed 60.1 decreased to ,45 (removing 50 normal samples). A histogram quality control step, as part of the GISTIC procedure, then removed tumours (n 5 51) with high degrees of non-tumour DNA contamination by looking for samples with only one peak of copy number across its whole genome. This histogram quality control step also removed normals (n 5 20) with tumour DNA contamination by looking for samples with greater than one peak of copy number across its whole genome.
GISTIC analysis. GISTIC analysis 12 was performed on arrays that met certain quality control criteria. Raw intensity value files from the GenePattern SNPfileCreator module were used as input into the GISTIC algorithm. In brief, batch correction, data normalization, copy-number determination using either the paired normal sample or the average of the five closest normal samples and copy number segmentation was performed. Data-set-specific copy number polymorphisms were identified by running GISTIC on the set of normal samples alone; the regions identified from this analysis were then also removed from the subsequent analysis of tumours. GISTIC then assigns G AMP and G DEL scores to each locus, respectively representing the frequency of amplifications (deletions) seen at that locus, multiplied by the average increase (decrease) in the log2 ratio in the amplified (deleted) samples. The score (G) is based on the average amplitude (a) of the lesion type (amplification or deletion) and its frequency (f) in the data set according to the formula: G i (lesion type) 5 f i (lesion type) a i (lesion type)
. The significance of each score is determined by comparison to similar scores obtained after permuting the data within each sample. The resulting q-value is an upper bound for the expected fraction of false positives among all regions with a particular q-value or less. GISTIC also implements a peel-off step, which identifies additional secondary peaks within a region.
GISTIC analysis was performed essentially the same as is described in a future publication 12 , with the following exceptions. Copy number determination was performed for each tumour using its matched normal sample when available and of good quality (n 5 242). For all others, the average of the five closest normal samples was used (n 5 129). Copy number segmentation was performed using the GLAD algorithm with parameter d 5 10. GLAD segments less than eight SNPs in length were also removed.
Regions identified by GISTIC were also compared to known copy-number polymorphisms 34 and were manually reviewed for the presence of the alteration in the paired normal sample. Focal deletion regions with events that occurred in tumour samples that did not have paired normal samples were considered presumed polymorphisms and also removed from the list. Secondary peaks and known and presumed germline copy number polymorphisms are listed in Supplementary Tables 12 and 13 . GISTIC analysis of large-scale regions. Significant broad regions of amplification and deletion were identified by applying GISTIC with the default thresholds of 2.14/1.87 (log2 ratio of 60.1). Regions identified by GISTIC that were greater than 50% of a chromosome arm were considered large-scale. Region frequencies were calculated by determining the number of samples that had a median log2 ratio greater/less than the threshold (60.1), for those SNPs within the region. GISTIC analysis of focal regions. Significant focal regions of amplification and deletion were identified by applying GISTIC with a threshold of 3.6/1.2 (log2 ratio of 0.848/20.737). Data visualization. Normalized raw copy number from GISTIC analysis was used as input for visualization in the GenePattern SNPviewer (http:// www.broad.mit.edu/cancer/software/genepattern/) 32 . Mapping information for SNP, Refgene and cytoband locations are based on Affymetrix annotations and the hg17 build of the human genome sequence from the University of California, Santa Cruz (http://genome.ucsc.edu). Chromosome arm analysis. After segmentation by GLAD, the median of each chromosome arm for each sample was calculated. Amplification or deletion of an arm across the data set was tested for significance by a two-sided binomial test, after removing log2 copy number ratios between 60.1. P values were falsediscovery rate (FDR) corrected to give a FDR q value; significance is set to a q value of 0.01. The standard deviation of the median copy number of significant arms was then used to sort samples into three groups. Higher standard deviation implies higher interchromosomal variation, which correlates with less stromal contamination. Frequencies were then calculated for the total set and for only the top one-third least stromally contaminated samples to give a better idea of true frequencies in the context of attenuated signal owing to stromal contamination. Comparison between tertiles. A similar chromosome arm analysis was performed independently on the three sample groups, separated according to the standard deviations of their median arm log2 copy number ratios. Amplification or deletion of an arm across the data set was tested for significance by a two-sided binomial test, after removing values between 60.0125. P values were FDR corrected to give a FDR q value, significance is set to a q value of 0.01. Estimation of stromal contamination. To attempt to estimate stromal contamination, we calculated the allele-specific copy numbers by taking all informative SNPs in each of the 237 tumours that have a paired normal (removing five bad pairs) and dividing the allele-specific signal from the tumour by that of the normal. Then for each SNP we found M, the minimum between the copy numbers of the A and B alleles. In regions in which one allele has zero copies (for example, one copy loss in diploid cells) M represents the stromal contamination level (as the stroma has one copy of each allele). We calculated the median value
